Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT07482228
Recruiting Observational

Long-term Clinical Outcomes After Retinal Artery Occlusion

NCT07482228 · tracked via the Priya Life Science South Korea tracker
Sponsor
Chonnam National University Hospital
Phase
Observational
Started
2026-03-01
Last updated
2026-03-19

Condition(s) studied

Retinal Artery Occlusion

Investigational drug(s) / intervention(s)

retinal artery occlusion

retinal artery occlusion: treatment for retinal artery occlusion

Study summary

Retinal artery occlusion (RAO) is a rare but vision-threatening vascular disorder that is commonly caused by embolic events originating from the heart or carotid arteries. Patients with RAO are known to have an increased risk of subsequent cardiovascular and cerebrovascular events, including ischemic stroke and myocardial infarction. However, long-term outcomes and optimal medical treatment strategies for these patients remain insufficiently characterized.

The purpose of this nationwide population-based study is to investigate the incidence of long-term cardiovascular and cerebrovascular outcomes in patients diagnosed with retinal artery occlusion using the Korean National Health Insurance Service (NHIS) database. In addition, the study aims to evaluate the impact of various medical therapies, including antiplatelet agents, anticoagulants, and statins, on long-term clinical outcomes.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients newly diagnosed with retinal artery occlusion Exclusion Criteria: * Patients with a prior diagnosis of retinal artery occlusion before the study period. * Patients diagnosed with giant cell arteritis.

Primary outcome measure(s)

  • Occurrence of MACCE — up to 5 years
    major adverse cardiovascular and cerebrovascular event

Trial sites (1)

FacilityCityRegionStatus
Chonnam National University Hospital Gwangju Gwangju Recruiting

More Chonnam National University Hospital trials in South Korea

Abbreviated Antithrombotic Therapy After PCI in Patients With AF and AMI Recruiting
Timing of FFR-guided PCI for Non-IRA in NSTEMI and MVD (OPTION-NSTEMI) Recruiting
Imaging and Physiologic Evaluation of Coronary Artery Disease Recruiting
Optimal Timing of Microaxial Flow Pump(Impella CP) in AMI-related Cardiogenic Shock Starting soon
Psychopharmacotherapy for Depressive Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07482228 on ClinicalTrials.gov ↗ ← All trials in South Korea